Search Results - "Anderson, K C"

Bone marrow microenvironment and the identification of new targets for myeloma therapy by Podar, K, Chauhan, D, Anderson, K C

“…The development of multiple myeloma (MM) is a complex multi-step process involving both early and late genetic changes in the tumor cell as well as selective…”
Get full text

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond by Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C

“…Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to treat or which regimen to use at MM…”
Get full text

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management by Kyle, R A, Durie, B G M, Rajkumar, S V, Landgren, O, Blade, J, Merlini, G, Kröger, N, Einsele, H, Vesole, D H, Dimopoulos, M, San Miguel, J, Avet-Loiseau, H, Hajek, R, Chen, W M, Anderson, K C, Ludwig, H, Sonneveld, P, Pavlovsky, S, Palumbo, A, Richardson, P G, Barlogie, B, Greipp, P, Vescio, R, Turesson, I, Westin, J, Boccadoro, M

“…Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older…”
Get full text

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics by Dimberg, L Y, Anderson, C K, Camidge, R, Behbakht, K, Thorburn, A, Ford, H L

“…Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies against TRAIL death receptors (DR) kill tumor cells while causing…”
Get full text

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications by Tai, Y-T, Landesman, Y, Acharya, C, Calle, Y, Zhong, M Y, Cea, M, Tannenbaum, D, Cagnetta, A, Reagan, M, Munshi, A A, Senapedis, W, Saint-Martin, J-R, Kashyap, T, Shacham, S, Kauffman, M, Gu, Y, Wu, L, Ghobrial, I, Zhan, F, Kung, A L, Schey, S A, Richardson, P, Munshi, N C, Anderson, K C

“…The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic target in human multiple myeloma (MM). Here we showed that chromosome…”
Get full text

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma by Ray, A, Das, D S, Song, Y, Hideshima, T, Tai, Y-T, Chauhan, D, Anderson, K C

Get full text

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival by Ohguchi, H, Harada, T, Sagawa, M, Kikuchi, S, Tai, Y-T, Richardson, P G, Hideshima, T, Anderson, K C

“…Recent studies have delineated cancer-type-specific roles of histone 3 lysine 27 (H3K27) demethylase KDM6B/JMJD3 depending on its H3K27 demethylase activity…”
Get full text

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma by Gullà, A, Hideshima, T, Bianchi, G, Fulciniti, M, Kemal Samur, M, Qi, J, Tai, Y-T, Harada, T, Morelli, E, Amodio, N, Carrasco, R, Tagliaferri, P, Munshi, N C, Tassone, P, Anderson, K C

“…Arginine methyltransferases critically regulate cellular homeostasis by modulating the functional outcome of their substrates. The protein arginine…”
Get full text

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells by Ray, A, Das, D S, Song, Y, Richardson, P, Munshi, N C, Chauhan, D, Anderson, K C

Get full text

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo by Morelli, E, Leone, E, Cantafio, M E Gallo, Di Martino, M T, Amodio, N, Biamonte, L, Gullà, A, Foresta, U, Pitari, M R, Botta, C, Rossi, M, Neri, A, Munshi, N C, Anderson, K C, Tagliaferri, P, Tassone, P

“…Interferon regulatory factor 4 (IRF4) is an attractive therapeutic target in multiple myeloma (MM). We here report that expression of IRF4 mRNA inversely…”
Get full text

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines by Maura, F, Petljak, M, Lionetti, M, Cifola, I, Liang, W, Pinatel, E, Alexandrov, L B, Fullam, A, Martincorena, I, Dawson, K J, Angelopoulos, N, Samur, M K, Szalat, R, Zamora, J, Tarpey, P, Davies, H, Corradini, P, Anderson, K C, Minvielle, S, Neri, A, Avet-Loiseau, H, Keats, J, Campbell, P J, Munshi, N C, Bolli, N

Get full text

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma by Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D.‐L., Schenkein, D. P., Anderson, K. C.

“…Summary In a phase 2 open‐label study of the novel proteasome inhibitor bortezomib, 54 patients with multiple myeloma who had relapsed after or were refractory…”
Get full text

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma by Minami, J, Suzuki, R, Mazitschek, R, Gorgun, G, Ghosh, B, Cirstea, D, Hu, Y, Mimura, N, Ohguchi, H, Cottini, F, Jakubikova, J, Munshi, N C, Haggarty, S J, Richardson, P G, Hideshima, T, Anderson, K C

“…Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC…”
Get full text

Clinically relevant end points and new drug approvals for myeloma by Anderson, K C, Kyle, R A, Rajkumar, S V, Stewart, A K, Weber, D, Richardson, P

“…This manuscript summarizes the recommendations of the American Society of Hematology/US Food and Drug Administration Workshop on Clinical Endpoints in Multiple…”
Get full text

Management of treatment-emergent peripheral neuropathy in multiple myeloma by Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, Sonneveld, P

“…Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects…”
Get full text

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma by Palumbo, A, Rajkumar, S V, Dimopoulos, M A, Richardson, P G, San Miguel, J, Barlogie, B, Harousseau, J, Zonder, J A, Cavo, M, Zangari, M, Attal, M, Belch, A, Knop, S, Joshua, D, Sezer, O, Ludwig, H, Vesole, D, Bladé, J, Kyle, R, Westin, J, Weber, D, Bringhen, S, Niesvizky, R, Waage, A, von Lilienfeld-Toal, M, Lonial, S, Morgan, G J, Orlowski, R Z, Shimizu, K, Anderson, K C, Boccadoro, M, Durie, B G, Sonneveld, P, Hussein, M A

“…The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer patients. The risk of VTE is…”
Get full text

Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance by Song, Y, Li, S, Ray, A, Das, D S, Qi, J, Samur, M K, Tai, Y-T, Munshi, N, Carrasco, R D, Chauhan, D, Anderson, K C

“…Proteasome inhibition is an effective therapy for multiple myeloma (MM) patients; however, the emergence of drug resistance is common. Novel therapeutic…”
Get full text

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials by JAGANNATH, S, RICHARDSON, P. G, SONNEVELD, P, SCHUSTER, M. W, IRWIN, D, STADTMAUER, E. A, FACON, T, HAROUSSEAU, J.-L, COWAN, J. M, ANDERSON, K. C

“…In multiple myeloma, deletion of chromosome 13 (del(13)) is associated with poor prognosis regardless of treatment. This study analyzed the impact of del(13)…”
Get full text

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) by Giralt, S, Stadtmauer, E A, Harousseau, J L, Palumbo, A, Bensinger, W, Comenzo, R L, Kumar, S, Munshi, N C, Dispenzieri, A, Kyle, R, Merlini, G, San Miguel, J, Ludwig, H, Hajek, R, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M A, Einsele, H, Barlogie, B, Anderson, K C, Gertz, M, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Sezer, O, Mateos, M V, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Richardson, P G, Niesvizky, R, Rajkumar, S V, Durie, B G M

“…Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell…”
Get full text

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials by Potts, B C, Albitar, M X, Anderson, K C, Baritaki, S, Berkers, C, Bonavida, B, Chandra, J, Chauhan, D, Cusack, Jr, J C, Fenical, W, Ghobrial, I M, Groll, M, Jensen, P R, Lam, K S, Lloyd, G K, McBride, W, McConkey, D J, Miller, C P, Neuteboom, S T C, Oki, Y, Ovaa, H, Pajonk, F, Richardson, P G, Roccaro, A M, Sloss, C M, Spear, M A, Valashi, E, Younes, A, Palladino, M A

“…The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration…”
Get more information